Investor Alert

press release

March 2, 2022, 8:01 a.m. EST

Dare Bioscience to Participate in Upcoming Conferences

SAN DIEGO, March 02, Mar 02, 2022 (GLOBE NEWSWIRE via COMTEX) -- SAN DIEGO, March 02, 2022 (GLOBE NEWSWIRE) -- Dare Bioscience, Inc. (NASDAQ: DARE ), a leader in women's health innovation, today announced that members of its management team will participate in the following conferences:

Cowen 42 [nd] Annual Health Care Conference

Therapeutic Area Partnerships (TAP): Accelerating Innovation in Women's Health

34 [th] Annual Roth Conference

  • March 13-15, 2022, Laguna Niguel, CA

  • Sabrina Martucci Johnson, President and CEO, will participate in the Emerging Therapies in Women's Health panel on March 14, 2022 at 8:00 a.m. PT. Ms. Johnson will also provide a company presentation, available on-demand beginning on March 11, 2022 at 5:00 a.m. PT

  • Panel webcast link: https://wsw.com/webcast/roth43/panel6/2041752

  • Presentation webcast link: https://wsw.com/webcast/roth43/dare/1801712

Archived webcasts will be available under "Presentations, Events & Webcasts" in the Investors section of the company's website at http://ir.darebioscience.com as follows:

  • Ms. Johnson's presentation at Cowen's 42 [nd] Annual Health Care Conference will be available until March 22, 2022.

  • The panel discussion and Ms. Johnson's presentation at the 34 [th] Annual Roth Conference will be available until March 28, 2022.

About Dare Bioscience

Dare Bioscience is a biopharmaceutical company committed to advancing innovative products for women's health. The company's mission is to identify, develop and bring to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, primarily in the areas of contraception, fertility, and vaginal and sexual health.

Dare's first FDA-approved product, XACIATO [TM] (clindamycin phosphate), is a lincosamide antibacterial indicated for the treatment of bacterial vaginosis in female patients 12 years of age and older. XACIATO is a clear, colorless, viscous gel, to be administered once intravaginally as a single dose. Dare's product portfolio also includes potential first-in-category candidates in clinical development: Ovaprene(R), a novel, hormone-free monthly contraceptive whose U.S. commercial rights are under a license agreement with Bayer; Sildenafil Cream, 3.6%, a novel cream formulation of sildenafil to treat female sexual arousal disorder utilizing the active ingredient in Viagra(R); and DARE-HRT1, a combination bio-identical estradiol and progesterone intravaginal ring for hormone therapy following menopause. To learn more about XACIATO [TM] , Dare's full portfolio of women's health product candidates, and Dare's mission to deliver differentiated therapies for women, please visit www.darebioscience.com .

Dare may announce material information about its finances, product and product candidates, clinical trials and other matters using the Investors section of its website ( http://ir.darebioscience.com ), SEC filings, press releases, public conference calls and webcasts. Dare will use these channels to distribute material information about the company, and may also use social media to communicate important information about the company, its finances, product and product candidates, clinical trials and other matters. The information Dare posts on its investor relations website or through social media channels may be deemed to be material information. Dare encourages investors, the media, and others interested in the company to review the information Dare posts in the Investors section of its website and to follow these Twitter accounts: @SabrinaDareCEO and @DareBioscience. Any updates to the list of social media channels the company may use to communicate information will be posted in the Investors section of Dare's website.


Investors on behalf of Dare Bioscience, Inc.:
Lee Roth
Burns McClellan


Media on behalf of Dare Bioscience, Inc.:
Jake Robison
Canale Communications

Source: Dare Bioscience, Inc.


Is there a problem with this press release? Contact the source provider Comtex at editorial@comtex.com. You can also contact MarketWatch Customer Service via our Customer Center.

(C) Copyright 2022 GlobeNewswire, Inc. All rights reserved.

Partner Center

Link to MarketWatch's Slice.